Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.

Methods and devices to capture and analyze aerosolized particles such as protein biomarkers and their truncated proteoforms characteristic of a disease, including a respiratory disease, in exhaled breath to enable rapid detection of diseases are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using one or more solvents and analyzed using devices including mass spectrometry.

Disclosed herein are biomarkers associated with a disease state such as lung cancer, and methods of discovering or using biomarkers. Also disclosed herein are classifiers built on biomarkers and methods of detecting the disease state in samples from subjects. The method may include obtaining a data set that includes protein information from a biofluid sample, and may involve using a classifier to identify the sample as indicative of a healthy state, a disease state, or a comorbidity.

The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.

The present disclosure provides methods and devices for early diagnosis of an infection, for example by the COVID-19 virus, and determining a course of action for treatment of the infection.

The present disclosure relates generally to compositions and methods for diagnosing and treating idiopathic pulmonary fibrosis (IPF). Also, methods for identifying IPF disease severity and likelihood for disease progression. An IPF patient can be identified when the CSF1 concentration or soluble CSF1R concentration in a blood sample is decreased as compared to a reference blood sample from a reference human subject not having IPF, and/or when the soluble CSF1R concentration in a bronchoalveolar lavage (BAL) fluid sample is increased as compared to a reference BAL fluid sample from the reference human subject. Once identified, the patient can be treated with, for instance, CSF1 or CSF1R inhibitors, such as antibodies. Moreover, the IPF patient soluble CSF1R level in blood or BAL samples can also be used to assess the severity of disease, and to both monitor disease progression and treatment outcomes.

The present disclosure provides a method for noninvasively diagnosing and staging a progressive chronic lung disease characterized by disease related lung dysfunction by deriving from a biological sample from a subject a purified enriched population of exosomes in the biological sample, wherein dysregulated expression of the two or more microRNAs, compared to a healthy control, comprises a signature of a fibrotic lung disease; and medically managing the diagnosed fibrotic lung disease as early as possible in the course of progression of the disease to reduce or slow its progression. The method may identify interstitial pulmonary fibrosis (IPF) at a stage before standard procedures (e.g., Ashcroft scoring and histology) demonstrate changes consistent with lung fibrosis.

The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

The invention provides diagnostic and therapeutic targets for pulmonary disease, in particular, fibrotic lung disease. The inventors have found that a genetic variant MUC5B gene is associated with increased expression of the gene, increased risk of developing a pulmonary disease, and an improved prognosis and survival among those developing the pulmonary disease.

The invention provides a method for identifying a subject suitable for receiving a lung transplant, the method comprising: subjecting a sample to mass spectrometry analysis (in the negative ion mode or positive ion mode; preferably in the positive ion mode) and generating a mass spectrum output; wherein said sample is an isolated sample obtained from a subject that is a candidate for receiving a lung transplant; detecting one or more peak set in said mass spectrum output; wherein the presence of said one or more peak set indicates that the subject is not a suitable candidate for receiving a lung transplant; or wherein the absence of said one or more peak set indicates that the subject is a suitable candidate for receiving a lung transplant. The invention relies on the detection of peak sets specific to the membrane of pathogens, in particular mycobacteria.